Teva scored a 100 out of 100 on the 2023-2024 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Teva Pharmaceuticals increases the risk of dividing employees, alienating customers and harming shareholders. The company provides a benefits package for employees which covers transgender medical procedures for covered employees and dependents, including children. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Teva Pharmaceuticals forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Teva Pharmaceuticals integrates ESG into its business practices. Teva is committed to carbon neutrality by 2050 and supports the Equality Act. The company's opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. Teva Pharmaceuticals is a corporate partner of the NGLCC. The company is a member of the Global Alliance for Responsible Media, which aims to demonetize advertisements and suppress content that “vilifies” individuals based on sexual orientation and gender identity, discusses “debated social issues in a negative or partisan context” or spreads “hate speech”. For these reasons, Teva Pharmaceuticals receives a High Risk rating.